AGM Presentation
Released
Released
Announcement PDF
ASX: PAA
AGM Investor Update
9 October 2024
Dr Michael Thurn
Disclaimer
This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by PharmAust Limited (ASX: PAA) (the “Company”). It does not purport to
contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any
information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of
the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this
presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent
decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute
discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this
presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations
Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or
similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in
isolation as a basis to invest in the Company.
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and
prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The
performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that
any particular rate of return will be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended,
recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results,
performance or achievements will be as expected, planned or intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as
defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of
any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from
registration including an exemption for qualified institutional buyers.
2
AGM Investor Update
Corporate Overview
Mid-stage biotechnology company targeting human neurodegenerative diseases
Share Price Performance
Capital Structure (AUD$)
Volume (m)
Last Price (AUD$)
0.50
25
0.45
0.40
20
0.35
Volume
0.30
SP
15
0.25
0.20
10
0.15
0.10
5
52 Week Low / High (PAA)
$0.20 / $0.10
$0.068/ $0.535
No. of Shares (PAA)
486,634,555
Listed Options (PAAOA)
116,315,955
Market Capitalisation
$94.9m
Cash (as at 30-Jun-24)
$10.7 m
Debt (as at 30-Jun-24)
Nil
Net Cash
$10.7m
Enterprise Value
$105.6m
Unlisted Options (10c/15c/17.5c)
0.05
0.00
7-Oct-23
Current Share Price (PAA/PAAOA)
7 October 2024
7-Nov-23
7-Dec-23
7-Jan-24
7-Feb-24
7-Mar-24
7-Apr-24
7-May-24
7-Jun-24
7-Jul-24
7-Aug-24
7-Sep-24
Enterprise Value (fully diluted)
$130.6m
Top Shareholders*
Board & Management
Hybrid Holdings Pty Ltd <Darcy Family Super Fund A/C>
4.57%
Mr GJ Van & Mrs GV Blommestein <Van Blommestein S/F A/C>
3.80%
Non-Executive Director
Dr Roger Aston
3.09%
Non-Executive Director
Mr Chek Loon Tan
1.80%
Board & Management
5.01%
Mr Sergio Duchini
Chairman & Non-Executive Director
Dr Michael Thurn
Chief Executive Officer & Managing Director
Mr Marcus Hughes
Dr Katie MacFarlane
Mr Stefan Ross
7-Oct-24
11.9 m
Company Secretary
* As at 7 October 2024
3
$10 million Placement completed in June, Share Purchase Plan for $7.8 million completed in July
AGM Investor Update
Investment Highlights
Derisked lead program in Amyotrophic Lateral Sclerosis (ALS) with multiple near-term catalysts and potential for use
in other neurodegenerative diseases
Global Opportunity for ALS
Positive Phase 1 Data in ALS
•
Repurposed drug with excellent long-term safety and tolerability profile
•
Monepantel (MPL) and its active metabolite, MPL Sulphone, detectable in cerebrospinal fluid
•
Promising early efficacy results showing potential to slow disease progression and increase life expectancy
•
Ongoing Open-Label Extension Study
•
Granted Orphan Drug Designation (ODD) by the US FDA
•
Accepted into the HEALEY ALS Platform Trial
4
diagnosis
• Limited treatment options
• Recent approvals list price >US$160,000
Strong Global IP Position
• Method of use patents issued
• ODD granted
• New manufacturing patent application
• Notice of allowance USPTO – MPL-6 Patent Family
• >200,000 people living with ALS worldwide
• Average life expectancy just over 2 years from
World Class Team
• Experienced Board and management team
• World class Scientific Advisory Board
• Industry leading collaborators and service
providers
Neurodegenerative Disease
Focus
• MPL has the potential to treat other
neurodegenerative diseases
• Accumulation of intracellular misfolded proteins is
a hallmark of most neurodegenerative diseases
• Testing underway in a range of preclinical models
AGM Investor Update
Clinical Development Phases
Rare diseases have the advantages of accelerated development timelines and lower development costs
Safety and
Tolerability
Early Discovery
Exploratory
IND
Standard
NDA
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Validation in ex
vivo cultures and
animal models
Determination of
safety and dose
finding
Analysis of
patient responses
to test treatment
Test of efficacy vs
standard therapy
and or placebo
Marketing of new
drug/therapy
<100 patients
100s patients
1000s patients
1000s patients
Phase 3
Phase 4
Preclinical
Rare
Disease
Post Approval
Confirmatory
Validation in ex
vivo cultures and
animal models
Phase 1
Phase 2
Determination of safety Analysis of patient Test of efficacy vs
and dose finding
responses to test standard therapy and
treatment
or placebo
Marketing of new
drug/therapy
100s patients
1000s patients
IND – Investigational New Drug; NDA – New Drug Application
5
AGM Investor Update
Regulatory Designations
Rare diseases have access to broad range of regulatory designations to reduce costs and accelerate development
Orphan Drug
Designation
Breakthrough
Therapy
Priority
Review
Orphan
Medicinal
Product
Designation
PRIME
Orphan Drug
Designation
Priority
Review
FDA
Fast Track
Central
Marketing
Authorisation
EMA
Conditional
Approval
TGA
Provisional
Approval
Accelerated
Approval
Exceptional
Circumstances
Provisional
Determination
Accelerated
Assessment
EMA – European Medicines Agency, FDA – Food and Drug Administration, TGA – Therapeutics Goods Administration
6
AGM Investor Update
Pipeline
Multiple synergistic product opportunities in neurodegenerative disease by repurposing monepantel
•
•
•
•
Single pivotal registration clinical study for ALS
Targeting accelerated approval from Phase 2 data
Access to HEALEY ALS Platform Trial reduces study cost and time, and increases patient participation rate
FDA approval in 2026 possible
Human Health
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Amyotrophic
Lateral Sclerosis
(Motor Neurone Diseases)
Neurodegenerative
Diseases
Pivotal registration
adaptive Phase 2/3
clinical study
HEALEY ALS
PLATFORM TRIAL
Approved /
Marketed
Accelerated approval
possible on Phase 2
data
Next Major Catalysts
• Regimen Specific Design
• Open IND
• HREC/IRB Approval
• First Patient In
• Identify Next Target Indication
• Preclinical Data
HREC – Human Research Ethics Committee; IND – Investigational New Drug; IRB – Institutional Review Board
7
AGM Investor Update
Focus on Neurodegenerative Diseases
Neurodegenerative
Diseases
Huntington
Disease
Alzheimer’s
Disease
Autophagy
Parkinson
Disease
Multiple
Sclerosis
Amyotrophic
Lateral
Sclerosis
8
AGM Investor Update
MND /ALS Pathology & Disease Progression
Characterised by progressive degeneration of nerve cells in the spinal cord and brain, MND/ALS affects the
voluntary control of the arms and legs, eventually leading to trouble with breathing and death
Normal Neuron
Mislocalization
Genetic factors
Environmental
factors
Aggregation
Monepantel
promotes autophagy
Degeneration
Autophagy is the natural
process the cell uses to
removes unnecessary or
dysfunctional or toxic
components through a
lysosome-dependent
regulated mechanism
Protein aggregation1 is an important feature of MND/ALS pathology. Amyloid deposits from different proteins such as TDP-43, C9ORF72 dipeptide
repeats, phosphorylated high molecular weight neurofilament protein, rho guanine nucleotide exchange factor, and FUS have been detected in MND/ALS
motor neurons. These aberrant protein deposits become toxic to the cells, leading to neurodegeneration and are targets for therapeutic interventions.
1Suk, T.R., Rousseaux, M.W.C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegeneration 15, 45 (2020). https://doi.org/10.1186/s13024-020-00397-1
9
AGM Investor Update
Meet Our Board of Directors
Sergio Duchini
Chairman & Non-Executive Director
Sergio serves as a Non-Executive Director
and Chair of the Audit Committee at Enlitic
Inc. Additionally, he holds the position of
Chair at Lymphoma Australia, a leading notfor-profit organization. Sergio previously sat
on the AusBiotech Board of Directors for
nine years. He also served as a Board
Director at Deloitte Australia, overseeing
the governance, strategy development, and
stewardship of the partnership.
10
Dr Michael Thurn
Managing Director & Chief Executive
Michael has over 25 years experience in
technical, regulatory, commercial and
management roles in research
organisations and industry, including early
stage, fast growing, private and publicly
listed biotechnology companies. Michael
has led a variety of US IND applications
across a range of therapeutic areas and
evaluated drugs and vaccines for
registration during his engagement at the
TGA.
Dr Katie MacFarlane
Non-Executive Director
Katie has over 30 years of experience in the
development and commercialisation of
pharmaceutical products and devices. She
has held senior executive positions at
Arkayli Biopharma, Agile Therapeutics,
Warner Chilcott, Parke-Davis (now Pfizer).
Katie currently serves on the Board of
Mayne Pharmaceuticals, an affiliate faculty
member of the Purdue University School of
Pharmacy and a Founding Member and
Advisor to IPhO.
Marcus Hughes
Non-Executive Director
Marcus brings more than 20 years’
experience with listed companies. He
possesses extensive corporate finance
experience, having led project financing
and capital raisings in the industrial sector.
He has held senior managerial, tax and
finance roles with multi-national companies
including Lend Lease, Fortescue Metals and
Rio Tinto
AGM Investor Update
Meet Our Management Team
John Clark
Chief Operating Officer
John has over 20 years of
pharmaceutical industry
experience in phase I – IV clinical
trials across numerous
therapeutic areas and multiple
geographical regions. John has a
thorough knowledge of ICH-GCP
and regulatory requirements and
held clinical operations leadership
roles responsible for
implementing global clinical
programs.
11
Dr Nicky Wallis
Chief Scientific Officer
Nicky is a neuroscientist and
brings over 12 years of global
expertise in clinical development,
spanning pre-clinical through to
Phase 3 drug and device
development. Her extensive
experience includes roles such as
Clinical Trials Program Specialist
at the Australian Clinical Trials
Alliance, Vice President of Clinical
Operations at Lateral Pharma
Biotech, and Clinical Project
Manager at Orygen Youth Mental
Health Research.
Dr Herbert Brinkman
Head of Manufacturing
Herb has over 30 years of
experience in the pharmaceutical
industry. He has prepared over 25
Chemistry Manufacturing and
Control sections and updates for
multiple filings for FDA and EU
regulatory agencies. Herb has
filed and commercially launched 9
products and contributed to filing
21 ANDAs for various semi-solid
and parenteral products. He is
also an inventor on 14 patents.
Dr Carol Worth
CMC Operations Manager
Carol brings over 30 years of
industry experience and a passion
for focusing on quality control and
quality assurance. She recently
served as Quality Manager at
Epichem Pty Ltd as Chief Technical
Officer at Suda Pharmaceuticals
and Solbec Pharmaceuticals. Carol
has also led product development
programs at Thermalife
International Pty Ltd/ Pharmasolv
Laboratories Pty Ltd
Lidija Damjanovic
Head of Marketing and
Corporate Affairs
Lidija brings over 15 years of global
experience and passion for
launching pharmaceutical products
and leading corporate
communications and affairs in the
biotech and pharmaceutical
industry. Her extensive leadership
experience in driving commercial
growth strategies includes marketing
and communications roles in
companies such as Merck Sharpe
and Dohme, Sartorius, Patheon and
other global organizations.
AGM Investor Update
MND / ALS Statistics & Treatments
There is no cure and MND/ALS is always fatal
Every 90 minutes
someone is
diagnosed and
dies with MND/ALS
90% of cases
occur without
a family
history
Onset is usually
between the ages of
40 & 70 years
Life expectancy on
average is just over
2 years
By 2040 the incidence
of MND/ALS is
expected to increase
by 70%
Current
Treatments
Qalsody (tofersen)
Developed to treat ALS associated with a
mutation in the superoxide dismutase 1
(SOD1) gene. The FDA approved Qalsody to
treat SOD1-ALS in 2023.
12
Rilutek (riluzole)
This was the first FDA-approved
drug available to treat ALS — in
1995. It inhibits glutamate release
and prolongs life ~3 months.
Radicava (edaravone)
The FDA approved Radicava
in 2017, making it the first new
treatment specifically for ALS in 22
years. Prolongs life ~6 months.
These drugs provide limited relief are controversial and slow disease progression by only months
AGM Investor Update
Phase 1
ALS MEND Study
The Phase 1 MEND Study was an open label, multicentre study involving 12 patients with ALS with the goal of
determining the recommended Phase 2/3 dose based on safety and preliminary efficacy
Study Design
Cohort 2
4 mg/kg
Group 1
6 Patients
Cohort 1
2 mg/kg
End of
Study
Group 2
6 Patients
SMC
SMC
Continue Treatment
Continue Treatment
Cohort 3
6 mg/kg
SMC
Compassionate-use
Program
SMC
Day 1
Open-Label Extension Study
12-months 10 mg/kg
Continue Treatment
12 Months
18 Months
30 Months
Treatment Period
SMC Safety Monitoring Committee
Study
Update
Cohort 4
10 mg/kg
• Positive top-line data released in Q1 CY24
• 12 patients continued treatment with monepantel under a compassionate-use program
• 10 patients have rolled-over into 12-month Open-Label Extension Study. Treatment continues to be very well-tolerated
• Updated ALSFRS-R and Survival Analysis to be generated by Berry Consultants.
• First group of 6 patients are entering their 24th month of continuous treatment with monepantel
• Phase 1 and baseline OLE data used to design of the protocol specific regimen in the HEALEY ALS Platform Trial
13
AGM Investor Update
Phase 1
Safety and Tolerability Summary
No deaths, no Serious Adverse Events related to treatment and a very low incidence of Adverse Events
Incidence of Adverse Event (n)
Dose 1 (2 mg/kg)
Dose 2 (4 mg/kg)
Dose 3 (6 mg/kg)
Dose 4 (10 mg/kg)
Total
Adverse Events
29
6
12
9
56
Related to Treatment
2
1
-
-
3
• Only 3 Adverse Events (mild in severity) possibly related to treatment
• Raised liver enzymes
• Increased hair growth
• Constipation
• No deaths
• No patients withdrew or were discontinued from the study
• One Serious Adverse Events (SAEs) reported that was unrelated to treatment
• 1 patient (Dose Level 3 – 6 mg/kg) - hospitalised for Intestinal dilatation and Pneumonia
14
AGM Investor Update
Phase 1
Preliminary Efficacy Amyotrophic Lateral Sclerosis Function Rating Scale – Revised (ALSFRS-R)
Treatment with monepantel for up to 12 months slowed the progression of ALS in all 12 patients by 39% when
compared to matched controls from the PRO-ACT database1
ALSFRS-R Domains Assessed
MPL – 39% Slower Decline in ALSFRS-R
Bulbar
PRO-ACT Matched
Controls (n=360) Monepantel (n=12)
• Speech
• Salivation
• Swallowing
0
Respiratory
Fine Motor
• Turning in bed
• Walking
• Climbing Stairs
• Handwriting
• Cutting food
• Dressing & hygiene
ALSFRS-R Slope (points/month)
• Dyspnea
• Orthopnea
• Respiratory
insufficiency
Gross Motor
Northeast ALS Consortium
(NEALS) clinically meaningful =
20% to 25% or greater change in
the slope of ALSFRS-R2
-0.2
-0.4
-0.6
-0.74
-0.8
-1
-1.2
-1.22
Difference
0.48 points/month (p=0.08)
-1.4
Each task is rated on a five-point scale from 0 = can't do, to 4 =
normal ability. Individual item scores are summed to produce a
reported score of between 0=worst and 48=best.
The PRO-ACT database is the largest publicly available repository of merged ALS
clinical study data. Data were pooled from 16 completed Phase 2/3 ALS clinical
studies and one observational study. Over 8 million de-identified longitudinally
collected data points from more than 8,600 persons with ALS, including
demographics, family histories, and longitudinal clinical and laboratory data.
1Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov
15
4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834.
2Castrillo-Viguera C, Grasso DL, Simpson E, et al. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler. 2010;11(1-2):178-180.
AGM Investor Update
Phase 1
Preliminary Efficacy Amyotrophic Lateral Sclerosis Function Rating Score – Revised (ALSFRS-R)
Dose response observed between Cohort 1 and 2. Rate of disease progression in Cohort 2 was slowed by an impressive
58% compared to the PRO-ACT database matched controls
Score ALSFRS−R +/− SE
SE Mean
Mean ALSFRS−R +/−ALSFRS-R
Cohort 1 and Matched Controls
16
48
FDA Timeframe for accelerated approval
40
Cohort 1
PRO−ACT
-0.83 points per month
Control
Monepantel
23% Slower Decline in ALSFRS-R
Cohort 1
Group
32
a
Monepantel
24
16
a
PRO-ACT
Matched Controls
N=210
N=7
N=155
N=7
N=175
N=7
N=159
N=7
N=162
N=7
N=138
N=7
N=159
N=7
N=123
N=7
N=126
N=6
N=106
N=6
N=119
N=6
N=107
N=6
N=111
N=5
0
1
2
3
4
5
6
7
8
9
10
11
12
Cohort 2 and Matched Controls
48
Time (Months)
FDA Timeframe for accelerated approval
40
Group
32
a
Monepantel
24
16
a
PRO-ACT
Matched Controls
N=150
N=5
N=107
N=5
N=118
N=5
N=120
N=5
N=114
N=5
N=96
N=5
N=116
N=5
N=87
N=5
N=78
N=3
0
1
2
3
4
5
6
7
8
Time
(Months)
Months of
Treatment
9
10
11
Cohort 2
PRO−ACT
Control
-0.60 points per month
Monepantel
58%
Slower Decline in ALSFRS-R
Cohort
2
12
AGM Investor Update
Phase 1
Exploratory Endpoints
No significant difference in ALS Quality of Life Questionnaire, Edinburgh Cognitive and Behavioural ALS Screen,
and Slow Vital Capacity between predose and end of treatment
ALSSQOL-R Quality of Life
Questionnaire
Edinburgh Cognitive and
Behavioural ALS Screen
10
8
160
140
5% Decrease
5
4
3
2
3.5
3.0
80
60
40
2.5
2.0
1.5
1
20
1.0
0
0
0.5
Predose
End of
Treatment
50-item questionnaire rated
on a 10-point scale, across 6
domain scores (negative
emotion, interaction with
people and environment,
intimacy, religiosity, physical
symptoms, and bulbar
function).
11% Decrease
4.0
100
6
ECAS Score
ALSSQOL-R Score
4.5
2% Increase
120
7
17
5.0
Litres
9
Slow Vital Capacity
Predose
End of
Treatment
Cognitive screening tool.
Includes assessment of
fluency, executive functions,
language, memory, and
visuospatial functions. The
total score is 136 points.
Predose
End of
Treatment
A lung function test that
measures how much air can
be exhaled out in a relaxed
manner until lungs are
completely empty.
AGM Investor Update
Phase 1
ALS Open Label Extension Study
Compared to matched controls from the PRO-ACT Historical Database, treatment with monepantel results in a
significantly (X2=12.83, p=0.0003) longer survival of patients with ALS
Berry Consultants Statistical Analysis
Overall Survival Probability
• Berry’s analysis involved comparing patients in the PRO-ACT
database with similar characteristics to those in PharmAust’s Phase
1 MEND Study adjusting for differing diagnosis durations
• Hazard ratio of 0.197 (95% CI: (0.062, 0.627), p = 0.0059) indicating that
treatment with MPL reduces the risk of death by 80.3%
Analysis Method
Log-Rank Test
Cox Proportional Hazards Model
Dataset
Death
Time
Imputation
2
p-value
Hazard
Ratio
95% CI
p-value
Assumed
Leave out
12.82
0.00034
0.197
(0.062,0.627)
0.0059
Assumed
Last Visit
14.07
0.00018
0.187
(0.059,0.593)
0.0044
Confirmed
Leave out
14.52
0.00014
0.186
(0.059,0.586)
0.0041
Confirmed
Last Visit
16.35
0.00005
0.173
(0.055,0.546)
0.0028
Current
patients
The PRO-ACT database is the largest publicly available repository of merged ALS
clinical study data. Data were pooled from 16 completed Phase 2/3 ALS clinical
studies and one observational study. Over 8 million de-identified longitudinally
collected data points from more than 8,600 persons with ALS, including
demographics, family histories, and longitudinal clinical and laboratory data.
1Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov
4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834.
18
AGM Investor Update
Monepantel Selected to Enter HEALEY ALS Platform Trial
The HEALEY ALS Platform Trial is a competitive process led by a group of expert ALS scientists and members of the
Healey & AMG Center Science Advisory Committee
HEALEY ALS Platform Trial1
FDA approved Master
Protocol
Active
Regimen
A
Active
Randomization
Active
Placebo
Active
Patient Enrolls
in Platform
Trial
Randomization
Regimen
B
Active
Randomization
Active
30% reduction in research cost
• The platform trial tests multiple treatments at once
reducing the cost of research
50% faster
• Trial times are cut in half due to the established
infrastructure and rapid recruitment
Placebo
Active
Regimen
C
Active
Randomization
Active
67% more participants
• The platform’s broad reach recruits more people and
brings them faster access to innovative therapies
Placebo
Shared infrastructure
and common protocol,
allowing sharing of
placebo participants
19
Shared
Placebo
1HEALEY ALS Platform Trial (https://www.massgeneral.org/neurology/als/research/platform-trial)
Placebo
Placebo
Placebo
Director of the Sean M.
Healey & AMG Center for ALS
at MGH, Chair of the
Department of Neurology,
and Principal Investigator of
the HEALEY ALS Platform
Trial
Prof Merit Cudkowicz
Co-Director, MGH
Neurological Clinical Research
Institute (NCRI) and Principal
Investigator of the HEALEY
ALS Platform Trial
Assoc. Prof Sabrina Paganoni
AGM Investor Update
Strategic Importance of the HEALEY ALS Platform Trial
Independent validation of monepantel’s potential as a treatment of ALS placing PharmAust in full view of potential
pharmaceutical partners
Pivotal Opportunity
• Independent validation of monepantel's potential as an
ALS treatment
• Leverages a network of leading ALS Neurologists across
the US
• Recognised by industry and the US FDA
• Fastest path to commercialization
Collaboration
• The trial is a large-scale collaboration across multiple
clinical trial sites, industry partners, and researchers
Exposure
• Increases reach within the ALS research community,
building on an existing partnership with Berry
Consultants to create global and US awareness
Funding
• Additional opportunities for non-dilutive and strategic
investments
20
Innovative Trial Structure
Design
• Shared master protocol
• >70 clinical sites across the US
• 3:1 active drug to placebo ratio
• 160-240 participants per regimen
• 5 regimens completed
• 2 regimens enrolment closed
Next Steps
• Approximately 3-month study design phase to create a
regimen-specific protocol amendment
• File master protocol amendment under MGH’s IND
• Open US IND for monepantel
• File protocol amendment under MGH’s IND
• PharmAust to supply monepantel
• Targeting enrolment Q4 CY 2024
AGM Investor Update
Comparisons of ALSFRS-R Rates of Declines Across Studies
Favourable comparisons to the completed regimens in the HEALEY ALS Platform Trial and
PRO-ACT Database1
Rate of Decline in ALSFRS-R (points/month +/- SEM)
-1.8
-1.6
-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
MPL Phase 1
MPL Cohort 1
MPL Cohort 2
PRO-ACT Controls P1
Phase 1 MEND Study2
PRO-ACT Cohort 1
PRO-ACT Cohort 2
OLE
Regimen A
Regimen B
Regimen C
Regimen D
HEALEY ALS Platform Trial3
Regimen E
All Regimens
PRO-ACT Controls
MPL = Monepantel, P1 = Phase 1
1Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi:
21
10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834.
2PharmAust Data on file.
3 Melanie Quintana, Eric Macklin*, Lori Chibnik, Joseph Marion, Anna McGlothlin, Michelle Detry, Matteo Vestrucci, Giorgio Paulon, Jeremy Shefner, Jinsy Andrews, James D. Berry, Marianne Chase, Hong Yu, Alexander Sherman, Sabrina Paganoni, Merit Cudkowicz,
for the HEALEY ALS Platform Trial Study Group. Statistical Innovation and Complexities in the HEALEY ALS Platform Trial: Lessons Learned From the First Set of Regimens. Poster Presentation. ENCALS meeting 2024 Stockholm, Sweden June 17-20 2024
AGM Investor Update
Rare Central Nervous System Disease Market
FDA granted monepantel orphan drug designation (ODD) status for the treatment of ALS. The global CNS rare disease
treatment market is expected to reach US$13.8 billion by 2027 (CAGR > 8.5%)1
Neurological disease deals by therapy type in
2022 and 2023 (October)2
Selected partnering deals in the CNS field in 20232
Preclinical
Preclinical
Preclinical
US$505 Million
License
June 2020
US$970 Million
License
March 2023
US$580 Million
License
September 2023
Hangzhou Highlightll
Over 49 deals were announced 2023
involving rare CNS diseases, with
disclosed deal values totalling more than
US$13.2 billion
Phase 1
Phase 1
Preclinical
US$728 Million
License
December 2023
US$122 Million
ex-US License
March 2024
US$612 Million
License
June 2024
Paul Field
Business Development Officer
Paul brings over 30 years of business
development experience across a range of
therapeutic areas, including
neurodegenerative diseases, and he
maintains a deep network in the global
biopharmaceutical industry. His
experience includes business
development roles at Cerecin, Marinova,
BioCurate and other companies, and he
serves on the Boards of NASDAQ-listed 60
Degrees Pharmaceuticals and Wintermute
Biomedical
1The Insight Partner March 2020
22
2Mark Zipkin, Neurodegeneration and rare diseases drive CNS therapy deals. Biopharma Dealmakers News Feature. 1 December 2023. doi: https://doi.org/10.1038/d43747-023-00128-7
AGM Investor Update
Research and Development Timeline
Derisked lead program in Amyotrophic Lateral Sclerosis (ALS) with multiple near-term catalysts and potential for use
in other neurodegenerative diseases
Timeline
✓ Pre-IND Meeting
✓ OLE HREC Approval
✓ Phase 1 MEND Study Top-line
✓ Board & Management Hires
✓ Orphan Drug Designation
✓ OLE Update
Share your feedback
Discover